Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver Disease
酒精相关性肝病患者肝移植候选者的选择
基本信息
- 批准号:10451532
- 负责人:
- 金额:$ 19.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AbstinenceAcuteAcute Alcoholic HepatitisAdrenal Cortex HormonesAlcohol consumptionAlcoholic HepatitisAlcoholic Liver DiseasesAlcoholsAttenuatedBehavioralBiological MarkersBiometryCessation of lifeChronicCirrhosisClinical InvestigatorCohort StudiesCollaborationsCommunitiesConsensusCountryDataDecision MakingDelphi TechniqueDevelopmentDevelopment PlansEuropeEvaluationEventFosteringFundingFutureGoalsGraft RejectionHepatitis CHepatologyInferiorInjuryInterventionInterviewKnowledgeLeadLiver diseasesMedicalMedicineMulticenter TrialsNational Institute on Alcohol Abuse and AlcoholismNatural HistoryOutcomePatientsPilot ProjectsPredictive AnalyticsProcessProgram DevelopmentProtocols documentationQuestionnairesRefractoryRelapseReproducibilityResearchResearch PersonnelResearch TrainingRiskRisk EstimateScienceScientistSelection CriteriaSocial supportStandardizationSurveysTransplant RecipientsTransplantationUnited StatesUniversitiesValidationWorkaddictionadverse outcomealcohol abstinencealcohol abuse therapyalcohol relapsealcohol researchalcohol screeningbasecandidate selectioncareer developmentcohortevidence baseexperiencefollow-upimprovedinterdisciplinary approachliver transplantationmembermortalitymortality risknon-alcoholic fatty liver diseasenovelpost-transplantpredictive modelingrelapse riskskillssobrietysubstance usesupportive environmenttooltransplant centers
项目摘要
PROJECT SUMMARY
Alcohol consumption is a major cause of liver disease worldwide. Severe alcoholic hepatitis (SAH), an acute
manifestation of alcohol-related liver disease (ALD), is associated with inferior short-term survival. Unfortunately,
there are few effective medical therapies for SAH outside of corticosteroids, to which about 40% of patients are
refractory. For these patients, liver transplantation (LT) is the only rescue treatment available. Until recently,
most transplant centers mandated at least six months of continuous abstinence from alcohol before LT.
Unfortunately, this “6-month rule” was(is) often unachievable for patients with SAH, due to recent alcohol use
and high short-term mortality. Several recent studies from Europe and the United States championed the concept
of early liver transplantation (ELT) in this highly vulnerable patient cohort, though post-LT alcohol relapse
remained a concern with adverse consequences like graft injury and cirrhosis.
To date, there is no consensus on the optimal LT candidate selection criteria in ALD, which can lead to uneven
and substandard post-LT outcomes, including alcohol relapse. This project will advance our field in several ways.
First, it will define the impacts of ELT and alcohol abstinence on the natural history of SAH. Second, it will develop
and validate a novel LT candidate selection tool in ALD. The project findings will support a planned multicenter
trial and R01 submission for the external evaluation of the candidate selection tool.
This proposed work represents an interdisciplinary approach toward the optimization and the standardization of
the LT candidate selection process in ALD. To conduct this study, I will integrate myself into the research
community of the NIAAA P50-funded Johns Hopkins DELTA Center for Alcohol Research, which will help me
establish a network of alcohol researchers for current and future collaboration. I will also actively engage in
formal coursework in biostatistics and addiction science as well as interdisciplinary career development
programs. Through the proposed career development plan, I will gain the necessary skills and experience to
establish myself as an independent clinical investigator bridging the fields of hepatology, transplantation, and
addiction medicine.
项目概要
饮酒是世界范围内导致严重酒精性肝炎(SAH)的主要原因。
不幸的是,酒精相关性肝病(ALD)的表现与短期生存率较低有关。
除了皮质类固醇外,对于 SAH 几乎没有有效的药物治疗方法,约 40% 的患者接受皮质类固醇治疗。
对于这些难治性的患者,肝移植(LT)是迄今为止唯一可用的挽救治疗方法。
大多数移植中心要求在 LT 之前至少连续戒酒六个月。
不幸的是,由于最近饮酒,这个“6 个月规则”对于 SAH 患者来说通常是无法实现的
欧洲和美国最近的几项研究支持了这一概念。
尽管 LT 后酒精复发,但早期肝移植 (ELT) 在这一高度脆弱的患者群体中的应用
仍然担心移植物损伤和肝硬化等不良后果。
迄今为止,对于 ALD 的最佳 LT 候选选择标准尚未达成共识,这可能导致不均匀
以及不合格的 LT 后结果,包括酒精复发。该项目将以多种方式推进我们的领域。
首先,它将定义 ELT 和戒酒对 SAH 自然史的影响。其次,它将发展。
并验证 ALD 中的新型 LT 候选者选择工具。该项目的研究结果将支持计划中的多中心计划。
试验和 R01 提交用于候选人筛选工具的外部评估。
这项拟议的工作代表了一种跨学科的方法来优化和标准化
ALD 中的 LT 候选人选择过程 为了进行这项研究,我将把自己融入到研究中。
NIAAA P50 资助的约翰霍普金斯 DELTA 酒精研究中心的社区,这将帮助我
我也将积极参与建立酒精研究人员网络以进行当前和未来的合作。
生物统计学和成瘾科学以及跨学科职业发展的正式课程
通过拟议的职业发展计划,我将获得必要的技能和经验。
使自己成为一名独立的临床研究者,在肝病学、移植和肝病学领域之间架起桥梁。
成瘾药。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Po-Hung (Victor) Chen其他文献
Po-Hung (Victor) Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Po-Hung (Victor) Chen', 18)}}的其他基金
Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver Disease
酒精相关性肝病患者肝移植候选者的选择
- 批准号:
10166736 - 财政年份:2020
- 资助金额:
$ 19.82万 - 项目类别:
Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver Disease
酒精相关性肝病患者肝移植候选者的选择
- 批准号:
10660978 - 财政年份:2020
- 资助金额:
$ 19.82万 - 项目类别:
相似国自然基金
Tenascin-X对急性肾损伤血管内皮细胞的保护作用及机制研究
- 批准号:82300764
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
活性脂质Arlm-1介导的自噬流阻滞在儿童T细胞急性淋巴细胞白血病化疗耐药逆转中的作用机制研究
- 批准号:82300182
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
- 批准号:82370165
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
KIF5B调控隧道纳米管介导的线粒体转运对FLT3-ITD阳性急性髓系白血病的作用机制
- 批准号:82370175
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
1/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
1/4-美国早期肝移植联盟-前瞻性酒精相关性肝病队列评估(ACCELERATE-PACE)
- 批准号:
10711811 - 财政年份:2023
- 资助金额:
$ 19.82万 - 项目类别:
4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
4/4-美国早期肝移植联盟-前瞻性酒精相关性肝病队列评估(ACCELERATE-PACE)
- 批准号:
10711018 - 财政年份:2023
- 资助金额:
$ 19.82万 - 项目类别:
3/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
3/4-美国早期肝移植联盟-前瞻性酒精相关性肝病队列评估(ACCELERATE-PACE)
- 批准号:
10711001 - 财政年份:2023
- 资助金额:
$ 19.82万 - 项目类别:
2/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
2/4-美国早期肝移植联盟-前瞻性酒精相关性肝病队列评估(ACCELERATE-PACE)
- 批准号:
10711336 - 财政年份:2023
- 资助金额:
$ 19.82万 - 项目类别: